J&J Buys License Option for Isis Pharma Bowel Drug

07.01.2015 - US over-the-counter drugmaker Johnson & Johnson will pay Isis Pharmaceuticals up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel...